Epidemiologicalfactors related to human monkeypox virus (MPOX) in men who have sex with men (MSM) in the United States
Project Number1F31AI178878-01A1
Former Number1F31AI178878-01
Contact PI/Project LeaderCARPINO, THOMAS
Awardee OrganizationJOHNS HOPKINS UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
Specific Aims: The overarching goal of this proposed study is to assess the factors associated with
monkeypox (MPOX) vaccination, testing, and stigma amongst men who have sex with men (MSM) in the
United States (US). Specially, we aim to 1. Evaluate determinants and disparities of MPOX vaccination
amongst MSM; 2. Characterize differences in MPOX testing uptake amongst MSM with MPOX-like symptoms;
3. Develop MPOX-specific stigma measures to evaluate the impacts of MPOX-related stigma amongst MSM.
Significance: Since May 2022, MPOX has been declared a public health emergency of international concern
with over 86,700 cases of MPOX in 110 countries/territories. Due to its widespread and rapid incidence, its
threat of endemicity or re-emerging outbreaks is significant. There is a growing but scarce body of literature
related to MPOX, with many unanswered questions related to disparities and determinants of vaccination,
testing, and stigma and how this will change in the coming years. Gay men have historically faced adverse
health effects compared to other reproductive aged adults, as witnessed in the global HIV/AIDS epidemic.
Furthermore, the emergence of COVID-19 has influenced accessibility of sexual health services and public
perception of infectious diseases, which could be leveraged to inform public health responses for MPOX and
future threats.
Approach: We will leverage data from approximately 10,000 MSM in the United States between 2022-2023
who participated in the American Men’s Internet Survey (AMIS). This proposed study is a rapid response to the
MPOX Epidemic using an innovative approach to understand trends and address unsolved questions in the
public health response. These data allow for assessment of higher level, contextual effects through developing
consistent metrics, to perform exploratory factor analysis and multilevel analysis of individual heterogeneity
and discriminatory accuracy (MAIHDA).
Training Information: Mr. Carpino’s training will consist of advanced infectious disease epidemiological
methodologies and social and behavioral factors. He will also incorporate contextual and structural level factors
and incorporate large data sources to apply analysis methods of observational data.
Public Health Relevance Statement
PROJECT NARRATIVE
The US Monkeypox (MPOX) Epidemic is a public health emergency of international concern which has
disproportionately affected gay and other men who have sex with men (MSM) in the United States (US).
Testing and pre-exposure prophylaxis for MPOX prevention (e.g., vaccination) promise to be efficacious
opportunities to abate the epidemic, but little data exists in the US to describe disparities and barriers to
uptake, such as stigma. Using a large cross sectional annual study of approximately 10,000 MSM in the US,
the American Men’s Internet Survey, we aim to 1) Evaluate determinants and disparities of MPOX vaccination
amongst MSM, 2) Characterize differences in MPOX testing uptake amongst MSM experiencing MPOX-like
symptoms, and 3) Develop MPOX-specific stigma measures to evaluate the impacts of MPOX-related stigma
amongst MSM.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AbateAccess to InformationAddressAdultAffectAgeAmericanAnxietyAwarenessBehaviorBehavioralBiologicalBiological FactorsBisexualCOVID-19Central AfricaCessation of lifeChillsClinicalCollaborationsCommunicable DiseasesCommunicationCommunitiesConstitutional SymptomCountryDataData SourcesDisparityDoseDrug usageEpidemicEpidemiologic FactorsEpidemiologyEthnic OriginExanthemaFactor AnalysisFeverFutureGaysGoalsHIVHIV/AIDSHealthHealth ServicesHealthcareHumanImmunocompromised HostIncidenceIndividualInfectionInfectious Disease EpidemiologyInternationalInternetKnowledgeLesionLiteratureLogistic RegressionsMeasuresMental DepressionMentorshipMethodologyMethodsModelingMonkeypoxMonkeypox virusOrthopoxvirusOutcomePainPerceptionPersonsPoliciesPopulationPositioning AttributePreventionPropertyPsychological FactorsPsychometricsPublic HealthRaceRecurrenceReportingResearchRiskRisk FactorsSexual HealthStigmatizationStructural RacismSubgroupSurveysSymptomsTarget PopulationsTechniquesTestingTrainingUnited StatesUniversitiesVaccinationVaccinesVirusWorkZoonosesaccess disparitiesagedcis-malecommunity-level factorexperiencehealth care availabilityhealth care servicehealth disparityindividual variationinnovationmarginalizationmembermenmen who have sex with menmortalitymultilevel analysisnew outbreakpre-exposure prophylaxispsychologicpublic health emergencyracial disparityreproductiveresponsesocialsocial stigmasociodemographicsstudy populationtesting servicestesting uptaketransmission processtreatment servicestrenduptakevaccine acceptancevaccine access
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
001910777
UEI
FTMTDMBR29C7
Project Start Date
01-June-2024
Project End Date
31-May-2026
Budget Start Date
01-June-2024
Budget End Date
31-May-2025
Project Funding Information for 2024
Total Funding
$48,974
Direct Costs
$48,974
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$48,974
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1F31AI178878-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1F31AI178878-01A1
Patents
No Patents information available for 1F31AI178878-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1F31AI178878-01A1
Clinical Studies
No Clinical Studies information available for 1F31AI178878-01A1
News and More
Related News Releases
No news release information available for 1F31AI178878-01A1
History
No Historical information available for 1F31AI178878-01A1
Similar Projects
No Similar Projects information available for 1F31AI178878-01A1